INTRODUCTION
Diabetes mellitus in pregnancy is a serious health problem associated with both fetal and maternal complications and has long term sequelae on both mother and child. Numerous biomarkers may differentiate GDM from normoglycemic pregnancy. Such as glycemic markers and hormonal markers like copeptin.
Copeptin is the stable carboxy terminal part of preprovasopressin and a surrogate marker of vasopressin. It is well documented that circulating levels of vasopressin are elevated in diabetic patients. It could result from a relative contraction of extracellular volume induced by glycosuria, and/or from an increased sensitivity of hypothalamic osmoreceptors to the plasma osmolarity.
AIM OF THE WORK
The aim of this study is to evaluate the use of maternal serum copeptin as a novel biomarker for development of GDM.
PATIENTS AND METHODS
Our study is a prospective cohort study conducted on 80 pregnant females 40 of them with high risk for GDM and another 40 pregnant women as control group. They were followed from the first antenatal visit to 24th-28th weeks of gestation.